Compare Marqeta Inc (MQ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Twist Bioscience Corp — how do they compare? Marqeta Inc trades at $17.79 (market cap $1.82B), while Twist Bioscience Corp trades at $160.26 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 5.5× Marqeta Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Twist Bioscience Corp for 27 Days on average.
| MQ | TWST | |
|---|---|---|
Market Cap | $1.82B | $10.08B |
Volume | 1,126,466 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $20.32 | $205.00 |
52-Week Low | $15.04 | $25.45 |
Typical Hold Time | 44 Days | 27 Days |
Enterprise Value | $1.13B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MQ trades at $17.06, up 3.08% today, with a bullish technical signal from moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue is projected to grow to $677 million in 2026, and net income turned positive in 2024 before a slight loss in 2025. Recent partnerships with BVNK for stablecoin-card infrastructure and Google for wallet expansion highlight strategic growth initiatives.
MQ shows improving fundamentals with revenue growth and recent profitability, but high valuation ratios (P/E of 193.83) pose a risk. The consensus price target of $11.38 suggests potential downside, though some analysts see upside to $18.00. Key risks include contract renewals in Q3 2026 and competitive pressures in the fintech sector. The stock's outlook hinges on execution of growth initiatives and sustained earnings improvements.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
